U.S. markets open in 5 hours 58 minutes
  • S&P Futures

    4,160.00
    +13.25 (+0.32%)
     
  • Dow Futures

    32,866.00
    +109.00 (+0.33%)
     
  • Nasdaq Futures

    13,286.25
    +57.50 (+0.43%)
     
  • Russell 2000 Futures

    1,928.00
    +6.20 (+0.32%)
     
  • Crude Oil

    90.08
    +1.07 (+1.20%)
     
  • Gold

    1,792.40
    +1.20 (+0.07%)
     
  • Silver

    20.00
    +0.16 (+0.80%)
     
  • EUR/USD

    1.0199
    +0.0011 (+0.11%)
     
  • 10-Yr Bond

    2.8400
    0.0000 (0.00%)
     
  • Vix

    21.76
    +0.32 (+1.49%)
     
  • GBP/USD

    1.2104
    +0.0034 (+0.28%)
     
  • USD/JPY

    135.1240
    +0.1540 (+0.11%)
     
  • BTC-USD

    23,791.98
    +777.97 (+3.38%)
     
  • CMC Crypto 200

    552.38
    +17.15 (+3.20%)
     
  • FTSE 100

    7,474.57
    +34.83 (+0.47%)
     
  • Nikkei 225

    28,249.24
    +73.37 (+0.26%)
     

Galera Therapeutics' Rucosopasem Shows Early Anti-Cancer Activity, Pulmonary Function Preservation

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Galera Therapeutics Inc (NASDAQ: GRTXannounced results from the open-label Phase 1 stage of the GRECO-1 trial of rucosopasem in combination with stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC).

  • Enrollment is ongoing in the randomized, double-blinded, placebo-controlled Phase 2 stage of the trial, with completion of enrollment anticipated in 2H of 2023.

  • Rucosopasem, in combination with SBRT, appeared well tolerated. The most frequent adverse events were fatigue, cough, and nausea, common in patients with lung cancer receiving radiotherapy.

  • Also See: Galera Posts Topline Data From Avasopasem Study In Chemoradiotherapy-Induced Esophagitis.

  • In-field partial responses or stable disease was seen in six of the seven patients at six months follow-up, including target tumor reductions in five patients of 61%, 58%, 33%, 29%, and 27% from baseline.

  • All seven patients are alive through a minimum of nine months of follow-up.

  • Early evidence of protection of pulmonary function was observed compared to the literature.

  • No Grade 2-4 declines in DLCO were seen in any of the seven patients receiving rucosopasem compared to a prospective trial (n=127) evaluating pulmonary function after four to five fractions of lung SBRT, in which 7-12% of patients had Grade 2-4 decline in DLCO.

  • Price Action: GRTX shares are down 12.30% at $1.35 during the market session on the last check Wednesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.